Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Pediatr Blood Cancer. 2012 Apr 5;59(7):1245–1251. doi: 10.1002/pbc.24152

Figure 2. Differential responses of pediatric AML cells to the combination of clofarabine and VPA.

Figure 2

The pediatric AML cell lines and diagnostic AML blast samples were divided into two groups based the median VPA IC50 (1.0 mM) measured by MTT assays. Cells with VPA IC50s ≤ 1.0 mM were defined as VPA-sensitive, while cells with VPA IC50 > 1.0 mM were defined as VPA-resistant. Fold decrease of clofarabine IC50s for pediatric AML cell lines and diagnostic AML blasts measured by MTT assays in the presence of 0.5 mM or lower VPA was compared with that from clofarabine alone. The horizontal lines indicate the median fold change in each group of AML cell lines and patient samples. The p value was determined by the nonparametric Mann-Whitney U test.